The FDA's request for additional time to review the supplemental new drug application for XHANCE directly impacts OptiNose's potential revenue and market position for this treatment. The delay is likely to be viewed negatively by investors, as it postpones the potential approval and commercialization of the drug, which is critical for the company's growth prospects. The significant premarket stock price drop reflects investor concerns over the delayed timeline.